Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 2, 2017, Pages 312-322

  Garcia Rodriguez S ^a   Arias Santiago S ^b   Blasco Morente, G ^b   Orgaz Molina, J ^b   Rosal Vela, A ^a   Navarro, P ^a   Magro Checa, C ^b,c   Martinez Lopez A ^b   Ruiz, J C ^b   Raya, E ^b   Naranjo Sintes, R ^b   Sancho, J ^a   Zubiaur, M ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CRYOPYRIN; FIBRINOGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; METHOTREXATE; MICRORNA; MICRORNA 146A; MICRORNA 155; MICRORNA 21; MICRORNA 223; MICRORNA LET 7I; SERUM AMYLOID A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; MIRN155 MICRORNA, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DOWN REGULATION; EXPLORATORY RESEARCH; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT DURATION; BLOOD; METABOLISM; MONOCYTE; PSORIASIS;

ADULT; FEMALE; HUMANS; MALE; MICRORNAS; MONOCYTES; PSORIASIS;

EID: 84994460550     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13861     Document Type: Article

References (57)

1. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012; 7: 385–422.
2. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 2008; 33: 312–315.
3. O'Connell RM, Kahn D, Gibson WS et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010; 33: 607–619.
4. Løvendorf MB, Skov L. MiRNAs in inflammatory skin diseases and their clinical implications. Expert Rev Clin Immunol 2015; 11: 467–477.
5. Hawkes JE, Nguyen GH, Fujita M et al. microRNAs in Psoriasis. J Invest Dermatol 2016; 136: 365–371.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.
7. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 2008; 18: 131–140.
8. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev 2013; 253: 146–157.
9. Grasedieck S, Sorrentino A, Langer C et al. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood 2013; 121: 4977–4984.
10. Zibert JR, Løvendorf MB, Litman T, Olsen J, Kaczkowski B, Skov L. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010; 58: 177–185.
11. Sonkoly E, Janson P, Majuri ML et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 2010; 126: 581–589.
12. Joyce CE, Zhou X, Xia J et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011; 20: 4025–4040.
13. Meisgen F, Xu N, Wei T et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol 2012; 21: 312–314.
14. Pivarcsi A, Meisgen F, Xu N, Ståhle M, Sonkoly E. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy. Br J Dermatol 2013; 169: 563–570.
15. Garcia-Rodriguez S, Arias-Santiago S, Orgaz-Molina J et al. Abnormal Levels of Expression of Plasma MicroRNA-33 in Patients With Psoriasis. Actas Dermosifiliogr 2014; 105: 497–503.
16. Koga Y, Jinnin M, Ichihara A et al. Analysis of expression pattern of serum microRNA levels in patients with psoriasis. J Dermatol Sci 2014; 72: 170–171.
17. Løvendorf MB, Zibert JR, Gyldenløve M, Røpke MA, Skov L. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 2014; 75: 133–139.
18. Xia J, Zhang W. MicroRNAs in normal and psoriatic skin. Physiol Genomics 2014; 46: 113–122.
19. Løvendorf MB, Mitsui H, Zibert JR et al. Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis. Exp Dermatol 2015; 24: 187–193.
20. Raaby L, Langkilde A, Kjellerup RB et al. Changes in mRNA expression precede changes in miRNA expression in lesional psoriatic skin during treatment with adalimumab. Br J Dermatol 2015; 173: 436–447.
21. Garcia-Rodriguez S, Arias-Santiago S, Perandres-Lopez R et al. Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 242–250.
22. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003; 148: 670–679.
23. Begon E, Michel L, Flageul B et al. Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur J Dermatol 2007; 17: 497–506.
24. Panzer R, Blobel C, Fölster-Holst R, Proksch E. TLR2 and TLR4 expression in atopic dermatitis, contact dermatitis and psoriasis. Exp Dermatol 2014; 23: 364–366.
25. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11: 163–175.
26. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481–12486.
27. Meisgen F, Xu Landen N, Wang A et al. MiR-146a Negatively Regulates TLR2-Induced Inflammatory Responses in Keratinocytes. J Invest Dermatol 2014; 134: 1931–1940.
28. Sheedy FJ, Palsson-McDermott E, Hennessy EJ et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141–147.
29. Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol 2015; 6(19): 1–9.
30. Chen XM, Splinter PL, O'Hara SP, LaRusso NF. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 2007; 282: 28929–28938.
31. Haneklaus M, Gerlic M, Kurowska-Stolarska M et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012; 189: 3795–3799.
32. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012; 22: 337–344.
33. Zhang L, Chopp M, Liu X et al. Combination Therapy With VELCADE and Tissue Plasminogen Activator Is Neuroprotective in Aged Rats After Stroke and Targets MicroRNA-146a and the Toll-Like Receptor Signaling Pathway. Arterioscler Thromb Vasc Biol 2012; 32: 1856–1864.
34. Liu PT, Schenk M, Walker VP et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS ONE 2009; 4: e5810.
35. Meisgen F, Xu Landén N, Bouez C et al. Activation of Toll-like receptors alters the microRNA expression profile of keratinocytes. Exp Dermatol 2014; 23: 281–283.
36. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008; 10: R101.
37. Kurowska-Stolarska M, Alivernini S, Ballantine LE et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A 2011; 108: 11193–11198.
38. Wang P, Hou J, Lin L et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 2010; 185: 6226–6233.
39. Lind EF, Ohashi PS. Mir-155, a central modulator of T-cell responses. Eur J Immunol 2014; 44: 11–15.
40. Forster SC, Tate MD, Hertzog PJ. MicroRNA as type I interferon-regulated transcripts and modulators of the innate immune response. Front Immunol 2015; 6(334): 1–9.
41. Tsoi LC, Spain SL, Knight J et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012; 44: 1341–1348.
42. Federici M, Giustizieri ML, Scarponi C, Girolomoni G, Albanesi C. Impaired IFN-γ-Dependent Inflammatory Responses in Human Keratinocytes Overexpressing the Suppressor of Cytokine Signaling 1. J Immunol 2002; 169: 434–442.
43. Zhang M, Liu F, Jia H et al. Inhibition of MicroRNA let-7i Depresses Maturation and Functional State of Dendritic Cells in Response to Lipopolysaccharide Stimulation via Targeting Suppressor of Cytokine Signaling 1. J Immunol 2011; 187: 1674–1683.
44. Chen Y, Liu W, Sun T et al. 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol 2013; 190: 3687–3695.
45. Li YC, Chen Y, Liu W, Thadhani R. MicroRNA-mediated mechanism of vitamin D regulation of innate immune response. J Steroid Biochem Mol Biol 2014; 144: 81–86.
46. Orgaz-Molina J, Magro-Checa C, Rosales-Alexander JL et al. Vitamin D insufficiency is associated with higher carotid intima-media thickness in psoriatic patients. Eur J Dermatol 2014; 24: 53–62.
47. Hunter MP, Ismail N, Zhang X et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008; 3: e3694.
48. Ismail N, Wang Y, Dakhlallah D et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood 2013; 121: 984–995.
49. Schulte LN, Westermann AJ, Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res 2013; 41: 542–553.
50. Saba R, Sorensen D, Booth S. MicroRNA-146a: A dominant, negative regulator of the innate immune response. Front Immunol 2014; 5(578): 1–11.
51. Xia P, Fang X, Zhang ZH et al. Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett 2012; 148: 151–162.
52. Tang Y, Luo X, Cui H et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065–1075.
53. Lofgren SE, Frostegard J, Truedsson L et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun 2012; 13: 268–274.
54. Castro-Villegas C, Pérez-Sánchez C, Escudero A et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther 2015; 17: 49.
55. Gu X, Nylander E, Coates PJ, Nylander K. Effect of narrow-band ultraviolet B phototherapy on p63 and microRNA (miR-21 and miR-125b) expression in psoriatic epidermis. Acta Derm Venereol 2011; 91: 392–397.
56. Guinea-Viniegra J, Jiménez M, Schonthaler HB et al. Targeting miR-21 to Treat Psoriasis. Sci Transl Med 2014; 6: 225re221.
57. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170–181.